Glycine-β-muricholic Acid
(Synonyms: Gly-MCA, GβMCA) 目录号 : GC40911
Glycine-β-muricholic Acid是一种有效的、稳定的、对精氨酸有选择性的口服生物活性FXR抑制剂，是鼠特异性初级胆汁酸β-鼠胆酸的甘氨酸结合形式。
Cas No.:66225-78-3
Sample solution is provided at 25 µL, 10mM.
Glycine-β-muricholic Acid is an effective, stable, and arginine-selective oral bioactive FXR inhibitor. It is the glycine-bound form of the murine primary bile acid β-muricholic acid. FXR is an important sensor and regulator of bile acid, lipid, and glucose metabolism [1]. Glycine-β-muricholic Acid can be used in studies of metabolic disorders [2].
In vivo, Glycine-β-muricholic Acid (10 and 50mg/kg; 5 weeks; oral) significantly reduced the absolute fat mass and fat-to-weight ratio of obese and insulin-resistant mice induced by HFD, as well as insulin resistance and hepatic steatosis, with a significant decrease in liver lipid droplets [1]. Glycine-β-muricholic Acid (10mg/kg/day; 23d once every 2 days; Gavage) treatment significantly reduced the protective effect of Lactobacillus reuteri on alcohol-induced lipid accumulation in the liver of mice. Lactobacillus reuteri and its metabolites may regulate liver inflammation through the FXR signaling regulatory axis [3].
References:
[1] Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
[2] Hasan M N, Wang H, Luo W, et al. Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice[J]. Journal of Lipid Research, 2024, 65(10).
[3] Cheng Y, Xiang X, Liu C, et al. Transcriptomic analysis reveals Lactobacillus reuteri alleviating alcohol-induced liver injury in mice by enhancing the farnesoid X receptor signaling pathway[J]. Journal of agricultural and food chemistry, 2022, 70(39): 12550-12564.
Glycine-β-muricholic Acid是一种有效的、稳定的、对精氨酸有选择性的口服生物活性FXR抑制剂，是鼠特异性初级胆汁酸β-鼠胆酸的甘氨酸结合形式。FXR是胆汁酸、脂质和葡萄糖代谢的重要传感器和调节因子 [1]。Glycine-β-muricholic Acid可用于代谢障碍的研究 [2]。
在体内，Glycine-β-muricholic Acid（10和50mg/kg; 5 weeks; oral）显著降低了HFD诱导的肥胖和胰岛素抵抗小鼠的绝对脂肪质量和脂肪/瘦体重比，以及胰岛素抵抗和肝脂肪变性，肝脏脂滴显著减少 [1]。Glycine-β-muricholic Acid（10mg/kg/day; 23d once every 2 days; gavage）显著降低了Lactobacillus reuteri对酒精诱导的小鼠肝脏脂质蓄积的保护作用，Lactobacillus reuteri及其代谢产物可能通过FXR信号调节轴调节肝脏炎症 [3]。
| Animal experiment [1]: | |
Animal models | C57BL/6N mice |
Preparation Method | For thermal neutral temperature exposure experiments, male 6-week-old C57BL/6N mice fed a HFD were orally administered with vehicle (control pills) or Glycine-β-muricholic Acid (0.25mg per pill per day, dose10mg kg−1) at 29.5°C for 2 weeks. For cold stimulation experiments, male 6-week-old C57BL/6N mice fed a HFD were orally administered with vehicle (control pills) or Glycine-β-muricholic Acid (0.25mg per pill per day, dose 10mg kg−1) at 22°C for 5 days and then acutely moved to 5°C for another 1 day. All mice were randomly assigned to experimental groups and the groups showed no difference in body weight gain before treatment. |
Dosage form | 10mg/kg/day for 5 days and two weeks; p.o. |
Applications | A short-duration 5-day treatment with Glycine-β-muricholic Acid specifically increases beige fat thermogenesis and energy expenditure before body weight change. |
References: | |
| Cas No. | 66225-78-3 | SDF | |
| 别名 | Gly-MCA, GβMCA | ||
| 化学名 | N-[(3α,5β,6β,7β)-3,6,7-trihydroxy-24-oxocholan-24-yl]-glycine | ||
| Canonical SMILES | O[C@@H]1CC[C@@]2(C)[C@@]([C@H](O)[C@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCC(O)=O)=O)([H])C1 | ||
| 分子式 | C26H43NO6 | 分子量 | 465.6 |
| 溶解度 | 20mg/mL in ethanol, or in DMSO, 20mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1478 mL | 10.7388 mL | 21.4777 mL |
| 5 mM | 0.4296 mL | 2.1478 mL | 4.2955 mL |
| 10 mM | 0.2148 mL | 1.0739 mL | 2.1478 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet